One 24-week clinical trial supports the role of etanercept for PPP, and further evidence of efficacy in several cases affected by SAPHO syndrome have been reported under different TNF-α-blocking agents (infliximab, adalimumab, and golimumab)49. This evidence concerns the gene TNF and palmoplantar pustulosis.